BPC-157 (Body Protection Compound, a 15-mer fragment derived from human gastric juice) is one of the most studied peptides in animal models of tissue regeneration. Its sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val is resistant to enzymatic hydrolysis, which explains its oral stability in preclinical studies.
Proposed signaling pathways
The preclinical literature converges on three main mechanisms:
- Modulation of the NO (nitric oxide) axis. Rodent studies show that BPC-157 can counteract inhibition of NO synthase, restoring local perfusion in injured tissues.
- Upregulation of VEGFR2. Increased expression of vascular endothelial growth factor receptor 2 has been observed, which is associated with accelerated angiogenesis at injury sites.
- Interaction with the serotonergic/dopaminergic system. This pathway is invoked to explain systemic effects observed in models of traumatic brain injury.
Evidence in tendon and muscle models
Work by Sikiric's group and collaborators (University of Zagreb) has documented, in murine models, accelerated healing of surgically transected Achilles tendons. Local and intraperitoneal administration in these models is associated with increased density of type I collagen fibers and a more orderly reorganization of the extracellular matrix in biopsies at 2–4 weeks post-injury.
It is important to stress that all this evidence comes from preclinical models. At the time of this review, there are no published phase 3 clinical trials that allow doses or safety to be extrapolated to humans.
Stability and handling in the laboratory
Lyophilized BPC-157 maintains activity for at least 24 months at -20 °C in a sealed vial. After reconstitution with bacteriostatic water, the literature suggests a shelf life of 28–30 days refrigerated (2–8 °C), although the research group should validate this parameter in its own protocol for the batch used.
Open questions in research
- Real bioavailability of the oral formulation in humans (contradictory data between laboratories).
- Characterization of the main receptor or receptors: to date, no single canonical receptor has been identified.
- Systemic pharmacokinetics after subcutaneous administration in primates: most data are in rodents.
Technical conclusion
BPC-157 is an excellent candidate for translational research in regeneration, but the field is still at the preclinical stage. The heterogeneity of published protocols (route, dose, animal model) makes replicability one of the main challenges for the coming years.
General references: Sikiric P. et al. — multiple publications in Current Pharmaceutical Design and Journal of Physiology Paris (2010–2023).
🔬 Updated on January 12, 2026 · Reviewed by the NeoPeptidos team · Content for research purposes (RUO).